News and Media

SOFIX was one of the most successful stock indices in 2021. The indicator outlined a successful trading on the Bulgarian Stock Exchange for both investors and public companies. For the twelve months of last year, the “blue chip” index grew by 42.23% to 635.68 points, showed a study by the newspaper. “Banker”. The main index of the Bulgarian Stock Exchange – SOFIX, ends 2021 in second place in terms of growth in the region of Central and Eastern Europe. It was outpaced only by OMX Tallin in Estonia, but only by a small margin /with 48.92% growth/.

For the second year in a row, the shares of Tchaikapharma High Quality Medicines Inc continue to gain value, and the drug manufacturing company also welcomes 2022 as the company with the largest market capitalization on the BSE-Sofia.

The pharmaceutical company started the 2021 stock exchange year at a share price of BGN 13.50 per unit. And twelve months later, the generic drug manufacturer’s shares added another BGN 1.40 to their value. Thus, the market capitalization of Tchaikapharma at the end of December reached BGN 1 259 050 000.

Not only the sector in which the company operates – the production of medicines – it supplies both potent products to leading international companies and generic ones produced in its plants in Plovdiv and Varna, but also its business plans and financial results support this growth of the shares.

Expansion activities at the tablet manufacturing facility in Plovdiv continue. The new equipment, which is in a test period, has been installed and staff has been trained. The construction of the additional warehouses for format parts has been completed and the premises are ready for start-up by the end of the year. The production permit is to be changed. Tihomir Kamenov controls 95.43% of the voting shares of the company.

BSE competitors on the “market capitalization” indicator also increased their market valuation, but are still far behind.

Read the full article here in Bulgarian.

Tchaikapharma High Quality Medicines obtained marketing authorisations for the Republic of Kosovo for the medicinal products Bilamcar 8 mg/5 mg; 16 mg/5 mg hard capsules and Ceftriaxon-Tchaikapharma 1 g; 2 g powder for solution for injection/infusion. The first deliveries are planned for early 2022.

Thus, the number of registered products of the company in Kosovo already exceeds 20.

The latest medicinal products to receive Marketing Authorization from the BDA and expand Tchaikapharma’s rich and diverse portfolio are:

– Tamaira Plus 5 mg/5 mg/12.5 mg; 5 mg/5 mg/25 mg; 10 mg/5 mg/25 mg hard capsules (with APIs ramipril, amlodipine and hydrochlorothiazide).

The medicinal product is indicated for the treatment of high blood pressure (hypertension) in adult patients adequately controlled with the individual products given concurrently at the same
dose level as in the combination, but as separate tablets.

The medicinal product is subject to medical prescription.

ATC code: C09BX03

– Rivaroxaban-Chaikapharma 10 mg; 15 mg; 20 mg film-coated tablets (rivaroxaban).

The medicinal product belongs to a group of medicines called antithrombotic agents. By its action, it blocks one factor of blood clotting (factor Xa) and thus reduces the ability of blood to form clots.

Rivaroxaban 10 mg – is used to prevent clots forming in veins after hip or knee replacement surgery. It is used to treat clots in the veins of the legs (deep vein thrombosis) and in the blood vessels of the lungs (pulmonary embolism), and to prevent their re-formation.

Rivaroxaban 15 mg; 20 mg – is used to prevent clots from forming in the brain (stroke) and in other blood vessels of the body if the patient has one type of cardiac arrhythmia called non-valvular atrial fibrillation. It is used to treat clots in the veins of the legs (deep vein thrombosis) and in the blood vessels of the lungs (pulmonary embolism), and to prevent them from forming again.

The medicinal product is subject to medical prescription.

ATC code: B01AF01

The first half of this year did not bring much of a stir in stock trading as a consequence of both the development of the pandemic and the slow recovery of the economy.

However, at the end of June this year, the Bulgarian Stock Exchange had a public company with a market capitalization of more than one billion leva.

The share prices of Tchaikapharma High Quality Medicines AD reflect the business plans and financial results of the company and its market cap is going up. In early July it confirms its position as the most expensive company on the Bulgarian Stock Exchange.

The full article is published in the financial media Banker.

Tchaikapharma Highquality Medicines, a flagship company on the Bulgarian pharma market, started trading shares on the Bulgarian Stock Exchange (BSE) on 21 May 2015. On today’s date exactly 6 years ago, the initial offering price per share was BGN 3.59, and on 21 May 2021 – BGN 14.10. This represents a growth of 292.757% over the entire period and a CAGR of 25.6%. This impressive increase does not take into account any dividend received in the form of new shares over the years, which further enhances the return on investment (ROI).

After its market cap surpassed BGN 1 billion at the end of June 2020, Tchaikapharma remains the most expensive company on the BSE with a capitalization of BGN 1,159,020,000.

At the beginning of this year, the company changed its stock code – it is now THQM as of 15 February 2021.